MANNKIND CORP
MNKDNASDAQTrading Snapshot
- Day Range
- $3.48 – $3.57
- 52-Week Range
- $2.23 – $6.51
- Volume (shares)
- 2,271,081
- Avg Volume (shares)
- —
- Shares Outstanding
- 321.5M
- Next Earnings
- 2026-11-10
Fundamentals Snapshot
- Annual Revenue
- $349M
- Last Q Revenue
- $109M
- P/E Ratio
- -24.6
- P/S Ratio
- 2.8x
- EPS (TTM)
- $-0.14
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +8.1%
MANNKIND CORP
MNKD
StockOtter · stockotter.spaceAbout MANNKIND CORP
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Latest News & Updates
MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that it will report third quarter 2026 financial results after market close on Thursday,
MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth
MannKind NASDAQ: MNKD Chief Executive Officer Mike Castagna said the company is advancing an inhaled version of nintedanib into a global Phase 2 study for idiopathic pulmonary fibrosis, or IPF, following early safety and
This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
MannKind to Participate in the Chardan Healthcare Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that Chief Executive Officer Michael Castagna will participate in a panel focused on inn
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)
New analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated comparable urine output to IV furosemide Consistent bioavailability, diuresis and natriuresis across injection sites support
MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum
MannKind NASDAQ: MNKD CFO Chris Prentiss outlined the company's commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major 2026 catalysts: expan